Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Jul 27, 2023; 15(7): 1423-1433
Published online Jul 27, 2023. doi: 10.4240/wjgs.v15.i7.1423
Table 1 Comparison of general data in each group
Items
Category
Radical resection group (n = 46)
Palliative group (n = 43)
t/χ2
P value
Age (yr)69.7 ± 10.270.3 ± 10.50.2730.785
GenderMale26250.9520.877
Female2018
Pathological typeAdenocarcinoma18160.7190.869
Mucus adenocarcinoma1412
Signet ring cell carcinoma1110
Non-adenocarcinoma35
Tumor locationWhole stomach980.186 0.979
Lower1816
Middle1211
Upper78
Table 2 Comparison of the patients’ relevant indicators between the two groups (mean ± SD)
Group
Palliative group (n = 43)
Radical resection group (n = 46)
t
P value
Operation time (min)275.32 ± 29.45281.34 ± 22.671.0850.281
Intraoperative blood transfusion volume (mL)356.45 ± 54.87286.0 ± 42.436.801< 0.001
Postoperative hospitalization duration time (d)14.54 ± 3.3713.43 ± 3.221.5890.116
Anal exhaust time (d)6.54 ± 1.434.62 ± 1.356.516< 0.001
Off-bed activity time (d)9.36 ± 1.386.87 ± 1.238.998< 0.001
Table 3 Comparison of the patients’ incidence rate of postoperative complications between the two groups, n (%)
Group
Palliative group (n = 43)
Radical resection group (n = 46)
χ2
P value
Postoperative bleeding2 (4.65)3 (6.52)--
Duodenal stump rupture2 (4.65)2 (4.35)--
Anastomotic obstruction1 (2.32)3 (6.52)--
Intestinal obstruction3 (4.35)2 (4.35)--
Abdominal effusion2 (4.65)1 (2.17)--
Reflux gastritis2 (4.65)3 (6.52)--
Incision infection1 (2.32)3 (6.52)--
Overall incidence rate12 (27.91)17 (39.96)0.4940.363
Table 4 Comparison of the patients’ relevant indicators of postoperative immune function between the two groups (mean ± SD)
Index of correlation
Palliative group (n = 43)
Radical resection group (n = 46)
t
P value
CD3+ (%)Pre-operation53.72 ± 3.6152.13 ± 4.211.9060.059
Post-operation50.12 ± 2.3263.52 ± 5.8114.100.043
CD4+ (%)Pre-operation31.92 ± 2.8330.81 ± 3.111.8570.067
Post-operation28.32 ± 2.4640.34 ± 3.0120.540.036
CD8+ (%)Pre-operation25.32 ± 2.1325.34 ± 2.041.5890.085
Post-operation27.24 ± 2.0525.22 ± 2.254.4170.033
CD4+/CD8+Pre-operation1.34 ± 0.321.32 ± 0.330.2890.773
Post-operation1.25 ± 0.341.63 ± 0.434.6030.065
CD3+/HLADR+Pre-operation7.23 ± 2.537.52 ± 2.621.5720.658
Post-operation6.35 ± 2.848.63 ± 3.141.7670.023
IgGPre-operation11.13 ± 1.5811.27 ± 1.270.5480.664
Post-operation14.68 ± 2.2818.35 ± 2.165.2560.037
IgMPre-operation3.24 ± 0.323.21 ± 0.280.3630.846
Post-operation3.56 ± 3.193.87 ± 0.533.2920.016
Table 5 Comparison of the patients’ levels of postoperative tumor markers and inflammatory factors between the two groups (mean ± SD)
Index of correlation
Palliative group (n = 43)
Radical resection group (n = 46)
t
P value
CEA (ng/mL)Pre-operation38.63 ± 3.4838.63 ± 3.480.4130.753
Post-operation15.36 ± 1.617.72 ± 0.724.9740.003
CA199 (U/mL)Pre-operation83.63 ± 5.6482.72 ± 5.820.3590.645
Post-operation33.27 ± 4.3918.57 ± 3.153.2920.012
CA125 (U/mL)Pre-operation65.34 ± 4.5464.43 ± 4.680.9310.354
Post-operation40.33 ± 3.2434.34 ± 3.668.1530.002
IL-6 (pg/mL)Pre-operation44.72 ± 7.3244.76 ± 7.320.7240.463
Post-operation36.87 ± 2.7727.47 ± 2.592.4720.015
IL-17 (pg/mL)Pre-operation64.32 ± 5.9662.46 ± 7.480.9340.723
Post-operation54.63 ± 6.2743.14 ± 5.692.7720.028
TNF-α (pg/mL)Pre-operation17.44 ± 2.3516.57 ± 2.280.5130.674
Post-operation9.36 ± 0.875.58 ± 0.464.5620.013
Table 6 Comparison of the patient’s postoperative quality of life between the two groups, n (%)
Item
Palliative group (n = 43)
Radical resection group (n = 46)
t
P value
EfficacyCR21 (48.84)35 (76.09)--
PR8 (18.60)8 (17.39)--
SD10 (23.26)3 (6.52)--
PD4 (9.30)0 (0.00)--
ORR29 (67.44)43 (93.48)0.0040.044
DCR39 (90.69)46 (100.00)0.1090.034
KPS scoreImproved23 (50.00)10 (23.26)0.0170.009
Stable14 (30.43)15 (34.88)0.8250.655
Ineffective9 (19.57)18 (41.86)0.0390.022
Effective37 (80.43)25 (58.14)0.0390.022
Table 7 Comparison of the patient’s postoperative survival rate between the two groups, n (%)
Item
Palliative group (n = 43)
Radical resection group (n = 46)
t
P value
Follow-up 6 moRecurrence rate 5 (11.63)3 (6.52)0.4000.638
Survival rate39 (90.71)46 (100.00)0.1090.034
Follow-up 1 yearRecurrence rate 6 (13.95)1 (2.17)0.0950.039
Survival rate34 (79.07)45 (97.83)0.01340.005
Follow-up 2 yearRecurrence rate 9 (20.93)1 (2.17)0.0130.005
Survival rate27 (62.79)40 (86.96)0.0170.008